ACE
vs
O
OMX Stockholm 30
ACE
Over the past 12 months, ACE has underperformed OMX Stockholm 30, delivering a return of +1% compared to the OMX Stockholm 30's +14% growth.
Stocks Performance
ACE vs OMX Stockholm 30
Performance Gap
ACE vs OMX Stockholm 30
Performance By Year
ACE vs OMX Stockholm 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Ascelia Pharma AB
Glance View
Ascelia Pharma AB engages in the research and development of pharmaceutical products for the treatment of cancer and cancer-related diseases. The company is headquartered in Malmo, Skane. The company went IPO on 2019-03-13. The firm identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The firm's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. The company has completed phase I of clinical studies.